500 related articles for article (PubMed ID: 17908458)
21. E-cadherin expression as a differentiation marker in gastric cancer.
Karayiannakis AJ; Syrigos KN; Chatzigianni E; Papanikolaou S; Karatzas G
Hepatogastroenterology; 1998; 45(24):2437-42. PubMed ID: 9951940
[TBL] [Abstract][Full Text] [Related]
22. The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients' survival.
Lazăr D; Tăban S; Ardeleanu C; Dema A; Sporea I; Cornianu M; Lazăr E; Vernic C
Rom J Morphol Embryol; 2008; 49(4):459-67. PubMed ID: 19050793
[TBL] [Abstract][Full Text] [Related]
23. E-cadherin, MMP-2, and MMP-9 as prognostic markers in penile cancer: analysis of 125 patients.
Campos RS; Lopes A; Guimarães GC; Carvalho AL; Soares FA
Urology; 2006 Apr; 67(4):797-802. PubMed ID: 16566971
[TBL] [Abstract][Full Text] [Related]
24. [A comparative study of E-cadherin mRNA expression in primary tumors and metastatic foci of gastric cancer].
Yang J; Dai DQ
Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):25-8. PubMed ID: 15771793
[TBL] [Abstract][Full Text] [Related]
25. [CpG island methylation of E-cadherin gene promoter in gastric carcinoma].
Zhou YN; Xu CP; Han B; Ji R
Ai Zheng; 2005 Oct; 24(10):1220-4. PubMed ID: 16219136
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) expression in relation to cadherin expression in patients with colorectal carcinoma.
Tsujitani S; Saito H; Honboh T; Ataka M; Tanida T; Makino M; Ikeguchi M
Dis Colon Rectum; 2007 Aug; 50(8):1241-9. PubMed ID: 17429708
[TBL] [Abstract][Full Text] [Related]
27. E-cadherin expression in early gastric carcinoma and correlation with lymph node metastasis.
Yi Kim D; Kyoon Joo J; Kyu Park Y; Yeob Ryu S; Soo Kim H; Kyun Noh B; Hwa Lee K; Hyuk Lee J
J Surg Oncol; 2007 Oct; 96(5):429-35. PubMed ID: 17786966
[TBL] [Abstract][Full Text] [Related]
28. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
Davidson B; Konstantinovsky S; Nielsen S; Dong HP; Berner A; Vyberg M; Reich R
Clin Cancer Res; 2004 Nov; 10(21):7335-46. PubMed ID: 15534110
[TBL] [Abstract][Full Text] [Related]
29. Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis.
Arnold SM; Young AB; Munn RK; Patchell RA; Nanayakkara N; Markesbery WR
Clin Cancer Res; 1999 Dec; 5(12):4028-33. PubMed ID: 10632335
[TBL] [Abstract][Full Text] [Related]
30. [Matrix metalloproteinase-2 and angiogenesis in gastric cancer].
Cai H; Kong ZR; Chen HM
Ai Zheng; 2002 Jan; 21(1):25-8. PubMed ID: 12500392
[TBL] [Abstract][Full Text] [Related]
31. The significances of lymph node micrometastasis and its correlation with E-cadherin expression in pT1-T3N0 gastric adenocarcinoma.
Kim JH; Park JM; Jung CW; Park SS; Kim SJ; Mok YJ; Kim CS; Chae YS; Bae JW
J Surg Oncol; 2008 Feb; 97(2):125-30. PubMed ID: 18095267
[TBL] [Abstract][Full Text] [Related]
32. E-cadherin expression in primary carcinomas of the breast and its distant metastases.
Kowalski PJ; Rubin MA; Kleer CG
Breast Cancer Res; 2003; 5(6):R217-22. PubMed ID: 14580257
[TBL] [Abstract][Full Text] [Related]
33. An immunohistochemical study of E-cadherin expression with correlations to clinicopathological features in gastric cancer.
Shun CT; Wu MS; Lin JT; Wang HP; Houng RL; Lee WJ; Wang TH; Chuang SM
Hepatogastroenterology; 1998; 45(22):944-9. PubMed ID: 9755986
[TBL] [Abstract][Full Text] [Related]
34. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance.
Chang HW; Chow V; Lam KY; Wei WI; Yuen A
Cancer; 2002 Jan; 94(2):386-92. PubMed ID: 11900224
[TBL] [Abstract][Full Text] [Related]
35. E-cadherin suppression accelerates squamous cell carcinoma progression in three-dimensional, human tissue constructs.
Margulis A; Zhang W; Alt-Holland A; Crawford HC; Fusenig NE; Garlick JA
Cancer Res; 2005 Mar; 65(5):1783-91. PubMed ID: 15753375
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium.
Shaco-Levy R; Sharabi S; Benharroch D; Piura B; Sion-Vardy N
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):226-32. PubMed ID: 18295959
[TBL] [Abstract][Full Text] [Related]
37. Expression of N-cadherin in esophageal squamous cell carcinoma and silencing expression of N-cadherin using RNA interference on invasiveness of EC9706 cells.
Li K; Wang X; He W; Lin N; Fan QX
Ai Zheng; 2009 Jan; 28(1):8-13. PubMed ID: 19448425
[TBL] [Abstract][Full Text] [Related]
38. [Correlation of E-cadherin hypermethylation to tumorigenesis and development of gastric cancer].
Liu WT; Jiao HL; Yang YL; Wang D; Zhang WM
Ai Zheng; 2007 Nov; 26(11):1199-203. PubMed ID: 17991318
[TBL] [Abstract][Full Text] [Related]
39. Effect of tumor-associated mutant E-cadherin variants with defects in exons 8 or 9 on matrix metalloproteinase 3.
Fuchs M; Hermannstädter C; Specht K; Knyazev P; Ullrich A; Rosivatz E; Busch R; Hutzler P; Höfler H; Luber B
J Cell Physiol; 2005 Mar; 202(3):805-13. PubMed ID: 15389640
[TBL] [Abstract][Full Text] [Related]
40. Expression of E-cadherin in cervical lymph nodes from primary oral squamous cell carcinoma patients.
Zhong LP; Li J; Zhang CP; Zhu HG; Sun J; Zhang ZY
Arch Oral Biol; 2007 Aug; 52(8):740-7. PubMed ID: 17331461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
